Vertos Medical develops minimally invasive treatments for lumbar spinal stenosis, centered on its mild Procedure. The company offers a procedure that targets chronic low back pain and has treated more than 70,000 patients in the United States. Demand for the mild Procedure is increasing significantly. Vertos plans to use new capital to expand patient access and to support research and development aimed at advancing care for chronic low back pain. The financing strengthens its commercial expansion efforts and capacity to scale adoption. Vertos positions itself to make a meaningful impact on mobility and quality of life for older adults with LSS. Vertos Medical Inc. is a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis (LSS). Its proprietary mild® technology is described as a safe, minimally invasive outpatient procedure that restores space in the spinal canal through an incision smaller than the size of a baby aspirin. The company emphasizes outpatient, low‑invasiveness approaches for LSS treatment. The announcement notes a significant equity investment from Partner Ventures. No financing size, operating metrics, or additional financial details were provided in the article. The company website is referenced for more information. Vertos Medical, based in Aliso Viejo, California, develops innovative, minimally invasive treatments for lumbar spinal stenosis (LSS). Its core product is the mild® procedure, an outpatient, fluoroscopically guided therapeutic LSS treatment that requires no general anesthesia, no implants, and no stitches. The mild procedure restores space in the spinal canal by removing hypertrophic ligamentum flavum through a 5.1-mm treatment portal using specialized devices. The company intends to use the financing to expand commercialization of mild® and to support physician training and education to broaden patient access. The company is led by President and CEO Eric Wichems. Vertos Medical recently closed a financing to support these commercial and training initiatives. Vertos Medical, based in Aliso Viejo, CA, develops and commercializes mild, a minimally invasive outpatient procedure for lumbar spinal stenosis (LSS). mild is performed through an incision the size of a baby aspirin, requires no general anesthesia, no implants and no stitches, and its efficacy and safety have been demonstrated in 11 clinical studies and more than 16 peer‑reviewed articles. Since receiving FDA 510(k) clearance in 2008, more than 15,000 people in the U.S. have been treated with mild, and the procedure has a reported 81% positive‑response rate. Vertos positions mild as a low‑cost, durable alternative to other LSS treatments, aiming to reduce complications and recovery time compared with open back surgery. The company announced it has closed nearly $23 million in a Series E financing led by Pitango Venture Capital to support commercial growth. Proceeds will be used for U.S. commercial expansion and to launch mild in European markets. Vertos Medical develops the mild procedure, a proprietary minimally invasive treatment for lumbar spinal stenosis (LSS). The mild procedure targets a large underserved group: patients who no longer respond to medical management but are not yet candidates for traditional invasive surgeries. The company is Aliso Viejo, CA-based and led by president and chief executive officer James M. Corbett. Vertos will use the Series D proceeds to continue U.S. commercialization of its mild technology. Company leadership described the financing as an important milestone and recognition of the market potential of the mild procedure.

Total raised

$93M

Funding rounds

5

Latest round

Series C

Latest activity

Jun 2023